September 2019 HSC Section 1 Congenital and Pediatric Problems

,QWHUQDWLRQDO -RXUQDO RI 3HGLDWULF 2WRUKLQRODU\QJRORJ\

²

H. Yankey, G. Isaacson

[26] N.K. Antonov, M.C. Garzon, K.D. Morel, S. Whittier, P.J. Planet, C.T. Lauren, High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pe- diatric population, Antimicrob. Agents Chemother. 59 (6) (2015) 3350 – 3356, http://dx.doi.org/10.1128/AAC.00079-15 Epub 2015 Mar 30. Erratum in: Antimicrob Agents Chemother. 2015 Nov;59(11):7158. [27] A.E. Simor, T.L. Stuart, L. Louie, C. Watt, M. Ofner-Agostini, D. Gravel, M. Mulvey, M. Loeb, A. McGeer, E. Bryce, A. Matlow, Canadian nosocomial infection surveil- lance Program, Mupirocin-resistant, methicillin-resistant Staphylococcus aureus

strains in Canadian hospitals, Antimicrob. Agents Chemother. 51 (2007) 3880 – 3886, http://dx.doi.org/10.1128/AAC.00846-07 . [28] K.H. Park, C.K. Lee, Mupirocin ointment prevents early post-tympanostomy tube otorrhea: a preliminary study, Korean J Audiol 16 (3) (2012 Dec) 130 – 133, http:// dx.doi.org/10.7874/kja.2012.16.3.130 Epub 2012 Dec 18. [29] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s020lbl.pdf . Accessed January 5, 2018.

154